Characterizing Tumor Thrombus Arising from Non–Clear Cell Renal Cell Carcinoma

Siegel, 2021, Cancer statistics, 2021, CA Cancer J Clin, 71, 7, 10.3322/caac.21654 Topaktaş, 2019, Surgical management of renal cell carcinoma with associated tumor thrombus extending into the inferior vena cava: a 10-year single-center experience, Turk J Urol, 45, 345, 10.5152/tud.2019.95826 Park H, Jeong CW, Yuk H, et al. Influence of tumor thrombus on occurrence of distant venous thromboembolism and survival in patients with renal cell carcinoma after surgery. Clin Appl Thromb Hemost 2019;25:1076029618823288. Psutka, 2015, Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma, Ther Adv Urol, 7, 216, 10.1177/1756287215576443 Reese, 2013, Natural history of untreated renal cell carcinoma with venous tumor thrombus, Urol Oncol, 31, 1305, 10.1016/j.urolonc.2011.12.006 Vuong, 2019, Tumor microenvironment dynamics in clear-cell renal cell carcinoma, Cancer Discov, 9, 1349, 10.1158/2159-8290.CD-19-0499 Bonsib, 2007, Renal veins and venous extension in clear cell renal cell carcinoma, Mod Pathol, 20, 44, 10.1038/modpathol.3800726 Kim, 2012, Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus, BJU Int, 110, E673, 10.1111/j.1464-410X.2012.11498.x Tilki, 2014, Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus, Eur Urol, 66, 577, 10.1016/j.eururo.2013.06.048 Kim, 2021, Determinants of renal cell carcinoma invasion and metastatic competence, Nat Commun, 12, 5760, 10.1038/s41467-021-25918-4 Quencer, 2017, Tumor thrombus: incidence, imaging, prognosis and treatment, Cardiovasc Diagn Ther, 7, S165, 10.21037/cdt.2017.09.16 Clavien, 2009, The Clavien-Dindo classification of surgical complications: five-year experience, Ann Surg, 250, 187, 10.1097/SLA.0b013e3181b13ca2 Master, 2018, The value of a cross-discipline team-based approach for resection of renal cell carcinoma with IVC tumor thrombus: a report of a large, contemporary, single-institution experience, J Surg Oncol, 118, 1219, 10.1002/jso.25271 Patard, 2005, Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience, J Clin Oncol, 23, 2763, 10.1200/JCO.2005.07.055 Margulis, 2008, Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma, Cancer, 112, 1480, 10.1002/cncr.23322 Wagner, 2009, Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma, Eur Urol, 55, 452, 10.1016/j.eururo.2008.07.053 Blute, 2004, The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus, BJU Int, 94, 33, 10.1111/j.1464-410X.2004.04897.x Neves, 1987, Surgical treatment of renal cancer with vena cava extension, Br J Urol, 59, 390, 10.1111/j.1464-410X.1987.tb04832.x Edge S, Byrd D, Frits A. AJCC cancer staging handbook. http://link.springer.com/book/9780387884424. Freifeld, 2019, Impact of hospital case volume on outcomes following radical nephrectomy and inferior vena cava thrombectomy, Eur Urol Oncol, 2, 691, 10.1016/j.euo.2018.10.005 Aizer, 2014, Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC), BJU Int, 113, E67, 10.1111/bju.12442 Choueiri, 2008, Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma, J Clin Oncol, 26, 127, 10.1200/JCO.2007.13.3223 Marchetti, 2021, The molecular characteristics of non-clear cell renal cell carcinoma: what’s the story morning glory?, Int J Mol Sci, 22, 6237, 10.3390/ijms22126237 Singla, 2019, Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma, Urol Oncol, 37, 924, 10.1016/j.urolonc.2019.08.012 Singla N, Margulis V. Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: a new surgical challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The next surgical frontier in kidney cancer: nephrectomy after immune checkpoint inhibition. Eur Urol 2020;78:e79–80. Singla N, Hutchinson RC, Ghandour RA, et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database. Urol Oncol 2020;38:604.e9–17. Labbate, 2019, Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy, J Immunother Cancer, 7, 66, 10.1186/s40425-019-0546-8 Hara, 2021, Pathological complete response of renal cell carcinoma with vena cava tumor thrombus to neoadjuvant TKI/IO combination therapy, Urol Case Rep, 39, 101800, 10.1016/j.eucr.2021.101800 Okada, 2020, Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab, Int Cancer Conf J, 9, 88, 10.1007/s13691-020-00403-9 Bakouny, 2021, Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma, Nat Commun, 12, 808, 10.1038/s41467-021-21068-9 Motzer, 2020, Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade, Cancer Cell, 38, 803, 10.1016/j.ccell.2020.10.011 Lee, 2022, Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates, J Clin Oncol Margulis, 2021, Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus-safety lead-in results of a phase 2 trial, Int J Radiat Oncol Biol Phys, 110, 1135, 10.1016/j.ijrobp.2021.01.054 Escudier, 2019, Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 30, 706, 10.1093/annonc/mdz056